Skip to main content
. Author manuscript; available in PMC: 2009 Nov 25.
Published in final edited form as: Stroke. 2009 May 28;40(8):2945–2948. doi: 10.1161/STROKEAHA.109.192535
Writing Group Member Employment Research Grant Other Research Support Speakers' Bureau/Honoraria Ownership Interest Consultant/Advisory Board Other
Gregory J. del Zoppo University of Washington none none none none none none
Harold P. Adams, Jr University of Iowa Grant to University of Iowa to provide continuing medical education on management of acute stroke (Genentech)* None Optum Health* (lecture on emergency treatment of stroke); National Stroke Association* (developed educational program for stroke care) None None None
Edward C. Jauch Medical University of South Carolina NIH grant (IMS3 Trial-Study Executive Committee) Novo Nordisk* None None Genentech* None
Jeffrey L. Saver University of California at Los Angeles Boehringer Ingelheim* Concentric* Concentric Medical*; Boehringer Ingelheim*; Ferrer* None CoAxia*; Talecris*; ev3*; Ferrer*; Concentric Medical*; Cygnis* NIH* (IMS3 Trial and CLEAR Trial)
This table represents the relationships of writing group members that may be perceived as actual or reasonably perceived conflicts of interest as reported on the Disclosure Questionnaire, which all members of the writing group are required to complete and submit A relationship is considered to be “significant” if (1) the person receives $10 000 or more during any 12-month period, or 5% or more of the person's gross income; or (2) the person owns 5% or more of the voting stock or share of the entity, or owns $10 000 or more of the fair market value of the entity. A relationship is considered to be “modest” if it is less than “significant” under the preceding definition.
* Modest.
Significant.